Mutation and deletion of the p53 tumor suppressor gene are arguably the most prevalent among the multiple genetic alterations found in human bladder cancer, but these p53 defects are primarily associated with the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogenes in tumor progression have yet to be defined. Using the mouse uroplakin II gene promoter, we have targeted into urothelium of transgenic mice a dominant-negative mutant of p53 that lacks the DNA-binding domain but retains the tetramerization domain. Urothelium-expressed p53 mutant binds to and stabilizes the endogenous wild-type p53, induces nuclear abnormality, hyperplasia and occasionally dysplasia, without eliciting frank carcinomas. Concurrent expression of the p53 mutant with an activated Ha-ras, the latter of which alone induces urothelial hyperplasia, fails to accelerate tumor formation. In contrast, the expression of the activated Ha-ras in the absence of p53, as accomplished by crossing the activated Ha-ras transgenic mice with the p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial papillary or high grade in nature. These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heterozygous p53 knockouts, is incapable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis.
Mutation and deletion of the p53 tumor suppressor gene are arguably the most prevalent among the multiple genetic alterations found in human bladder cancer, but these p53 defects are primarily associated with the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogenes in tumor progression have yet to be defined. Using the mouse uroplakin II gene promoter, we have targeted into urothelium of transgenic mice a dominant-negative mutant of p53 that lacks the DNA-binding domain but retains the tetramerization domain. Urothelium-expressed p53 mutant binds to and stabilizes the endogenous wild-type p53, induces nuclear abnormality, hyperplasia and occasionally dysplasia, without eliciting frank carcinomas. Concurrent expression of the p53 mutant with an activated Ha-ras, the latter of which alone induces urothelial hyperplasia, fails to accelerate tumor formation. In contrast, the expression of the activated Ha-ras in the absence of p53, as accomplished by crossing the activated Ha-ras transgenic mice with the p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial papillary or high grade in nature. These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heteroIntroduction p53 is a nuclear phosphoprotein that plays a central role in controlling cell growth and maintaining genome stability (Levine, 1997) . Normally short lived and present at very low levels, p53 can dramatically increase in response to stress signals such as DNA damage, hypoxia and oncogene activation (Ferbeyre et al., 2002) . The activated p53 transactivates a range of target genes, leading to cell cycle arrest, senescence or apoptosis (Gottifredi et al., 2000) . The role of p53 in these cellular processes is critical because it provides a fail-safe mechanism that prevents cells harboring genetic lesions from multiplying. When this surveillance mechanism ceases to function, affected cells can undergo uncontrolled growth, acquiring additional genetic defects and resulting in tumor formation. This explains why p53 is defective in more than half of all human tumors, making it the most frequently altered tumor suppressor gene (Soussi, 2000) .
Structural abnormalities of the p53 gene are prevalent in human bladder cancer (Knowles, 2001; Pohar and Cordon-Cardo, 2002; Theodorescu, 2003) . One p53 gene allele is frequently mutated, resulting in stabilized, yet nonfunctional p53 mutant protein, which is readily detectable by immunohistochemistry. In addition, the contra-lateral allele is often deleted, thus implying that p53 is nonfunctional in a significant portion of human bladder cancer. Interestingly, the p53 abnormalities are rare in low-grade, superficial papillary tumors, but are common in high-grade, invasive tumors, raising the possibility that loss of p53 function is responsible for the genesis of invasive tumors and predisposes bladder tumor progression (Koss, 1992; Cordon-Cardo et al., 1994; Spruck et al., 1994; Knowles, 1995; Orntoft and Wolf, 1998) . Indeed, a number of retrospective studies indicated that patients harboring p53 defects have a much higher probability of disease progression than those who do not, and that p53 status is a useful prognostic indicator, independent of tumor grade and stage, for predicting tumor recurrence and survival (Sarkis et al., 1993 Lacombe et al., 1996 ; Cordon-Cardo and Sheinfeld, 1997; Dahse et al., 2000; Fradet and Lacombe, 2000; Llopis et al., 2000; Reiher et al., 2002) .
Despite these advances, many critical questions remain regarding the biological role of p53 deficiency in urothelial growth and transformation. For instance, p53 abnormalities are detected mainly in late stages of bladder cancer, where many other genetic abnormalities are present (Messing, 1992; Sandberg and Berger, 1994; Liebert and Seigne, 1996; . It is unclear, therefore, whether p53 deficiency alone is capable of initiating urothelial tumor formation or whether it requires cooperative genetic events. A candidate cooperative event is activation of the ras signaling pathway, which is known to exist in human bladder cancer frequently. As many as half of the bladder cancer patients have either activating mutations of the Ha-ras gene or overexpression of the ras protein (Czerniak et al., 1992; Fitzgerald et al., 1995; Vageli et al., 1996) . Additionally, a similar percentage of the patients overexpresses epidermal growth factor receptor, which is known to activate the ras signaling pathway (Messing, 1992; Prenzel et al., 2001) . Recent in vitro studies have indeed revealed a collaborative relationship between Ha-ras activation and p53 deficiency. For example, transfection of primary-cultured fibroblasts harboring functional p53 with mutated Ha-ras leads to a dramatic increase of p53 and premature cellular senescence, whereas transfection of fibroblasts lacking p53 with mutated Ha-ras efficiently transforms the fibroblasts (Zambetti et al., 1992; Kikuchi-Yanoshita et al., 1995; Serrano et al., 1997; Ferbeyre et al., 2002) . These data suggest that p53 deficiency can potentiate with Ha-ras activation to induce tumorigenesis. It remains unclear, however, whether such a collaborative effect can occur in vivo and in urothelial cells. The difficulty of addressing these questions with clinical or in vitro materials calls for the development of in vivo experimental systems.
The recent isolation of the mouse uroplakin II gene promoter has allowed us to use the transgenic mouse models to study the biological roles of genetic alterations in urothelial tumorigenesis. This promoter exhibits several properties that are important for transgenesis: (1) it functions in a strictly urothelium-specific manner; (2) it is active in all mouse urothelial layers, including the basal layer that is more susceptible to oncogenic transformation; and (3) its expression persists even after malignant transformation (Lin et al., 1995; Zhang et al., 1999) . Using this promoter to develop transgenic mouse models, we found that urothelial expression of an activated Ha-ras can induce urothelial hyperplasia and low-grade, superficial papillary tumors (Zhang et al., 2001) . The onset of the bladder tumors depends on the dosage of the uroplakin II-Ha-ras transgene, as mice harboring 30-50 copies of the transgene develop tumors at 4-5 months of age and mice harboring 1-2 copies of the transgene develop only urothelial hyperplasia before 10 months of age, after which 63% of the mice develop the bladder tumors (Zhang et al., 2001) . In an independent study, urothelial expression of an SV40T antigen, which is known to inactivate functionally p53 and pRb tumor suppressor proteins (Bryan and Reddel, 1994) , elicits high-grade, invasive bladder cancer (Zhang et al., 1999) . The severity of the SV40T-induced bladder tumor is also dependent on the transgene dosage. While high-copy-numbered mice develop fast-progressing invasive and metastatic tumors, low-copy-numbered mice consistently develop bladder carcinoma in situ (CIS). Interestingly, these bladder CIS lesions can persist over a 10-month period without progression or regression, during which the majority (86%) of CIS loses one of the p53 alleles (Cheng et al., 2003) . The fact that one p53 allele is lost and that p53 protein made by the remaining allele is subjected to SV40T inactivation suggests that p53 is nonfunctional in the bladder CIS. This situation is highly reminiscent of high-grade human bladder cancer, where one p53 allele is often lost and another allele is mutated (Pohar and Cordon-Cardo, 2002) . Our results in SV40T transgenic mice suggest that the loss of p53 function is important for the genesis and maintenance of bladder cancer. However, since the SV40T also inactivates pRb (Bryan and Reddel, 1994) , it cannot be ruled out that at least some of the tumorigenic effects of SV40T can be attributed to pRb dysfunction.
To further understand the contribution of p53 deficiency, alone or in combination with oncogenes, in bladder tumorigenesis, we have generated transgenic mice expressing a dominant-negative mutant of p53 in urothelium. This p53 mutant, which lacks the DNAbinding domain and retains the tetramerization domain, was shown previously to bind and inactivate the wild-type p53, immortalize primary-cultured fibroblasts, and, in conjunction with myc or activated Ha-ras, transform cultured fibroblasts (Shaulian et al., 1992; Bowman et al., 1996) . The mutant, therefore, possesses all the characteristics of naturally occurring p53 mutants identified in human tumors. We also studied the potential synergism between the expression of the p53 mutant and the expression of activated Ha-ras. Finally, we examined whether the total absence of p53, as occurring in p53 knockout mice (Donehower et al., 1992) , can collaborate with Ha-ras activation in initiating bladder tumorigenesis. The whole-body knockout of p53 in mice provided convincing evidence that p53 acts as a general tumor suppressor, but it yielded relatively little insight into the role of p53 in urothelial tumorigenesis. This is largely because the p53 knockouts succumb to lymphomas and soft-tissue sarcomas at early ages before their urothelia develop any phenotypic alterations. By crossing the p53 knockouts with Ha-ras transgenic mice, we were able to analyse the potential synergy between these two common genetic defects in bladder tumor formation. Together, these studies have allowed us to better define the role of p53 deficiency in bladder tumor initiation and progression.
Results

Urothelium-specific expression of a dominant-negative mutant of p53
To examine the role of p53 deficiency in urothelial growth and transformation, we generated transgenic mice harboring a dominant-negative form of p53 gene under the control of the mouse uroplakin II promoter ( Figure 1a ). Two transgenic lines (F2 and F8) were obtained ( Figure 1b) , both expressing the truncated form of p53 mRNA in the urothelium (Figure 1c ), but not in any nonurothelial tissues (data not shown). Crossbreeding among F8 offspring yielded a third line that was homozygous for the p53 mutant transgene (Figure 1d ). Phenotypic analyses of all three transgenic lines yielded similar results. A polyclonal antibody against p53 detected a 17-kDa p53 mutant along with a 53-kDa wild-type p53 in transgenic mice (Figure 2a , lanes 3 and 4). In contrast, both the mutant and wildtype forms of p53 were undetectable in nontransgenic mice ( Figure 2a , lane 2). This is consistent with the fact that under normal conditions p53 is short lived, and suggests that the transgenically expressed p53 mutant was able to bind to and form stable, yet nonfunctional oligomers with the endogenous p53 (Shaulian et al., 1992) . The overexpressed p53 was localized immunohistochemically to the nuclei of all urothelial layers, with stronger labeling associated with the umbrella cells (Figure 2b ), consistent with the known expression of the uroplakin II promoter. Although the immunohistochemical staining by polyclonal p53 antibody does not distinguish the mutant p53 from the wild-type p53, the majority of the p53 staining could be attributed to the mutant p53 as established by Western blotting (Figure 2a ). Taken together, these results established Figure 1 Generation of transgenic mice expressing a dominantnegative mutant of p53 in urothelium. (a) A chimeric gene consisting of a 3.6 kb mouse uroplakin (UP) II promoter, a 0.32 kb truncated cDNA fragment of mouse p53 encoding the first 14 and last 89 amino acids, and a 0.1 kb mouse protamine 1 (mp1) gene fragment containing a polyA signal. ATG marks translation initiation site within the p53 deletion mutant. P1 and P2 denote locations of probes for Southern blot analyses. Abbreviations for restriction enzymes are: K, KpnI; Bx, BstXI; B, BamHI; and H, HindIII. (b) BstXI-digested genomic DNA of tail biopsies were hybridized with P1 and P2 probes. Note the that two transgenic founder mice harbor a 3.1 kb (line 2) and a 4.6 kb (line 8) transgene restriction fragment, representing a head-to-tail and tail-to-tail orientation, respectively. Endogenous UPII (2.9 kb) and mp1 fragments (2.2 kb) were present in all mice, including the negative controls (À). (c) Detection of mRNA of the p53 mutant by RT-PCR. Note the expression of a 317 bp p53 mutant in the two transgenic lines (lanes 3-6), but not in negative controls (lanes 1 and 2). Also note the detection of a 1.3 kb endogenous wild-type p53 product in all mice. GAPDH (lower panel) was used as a RT-PCR loading control. (d) Southern blotting of NcoI-digested genomic DNA showing well-resolved 1.1 kb transgene and 1.4 kb endogenous UPII fragment, and the generation of homozygous ( þ / þ ) mice of line 8 harboring twice as much the transgene (1.1 kb) as the heterozygotes ( þ /À) Figure 2 Urothelium-expressed p53 mutant binds to and stabilizes endogenous wild-type p53. (a) Western blot analysis. Total urothelial proteins from transgenic and nontransgenic mice were solubilized with 5% SDS, resolved by 10% SDS-PAGE and reacted with a polyclonal antibody against p53 (Ab-7). The reaction was visualized with a chemiluminescent method. Note the expression of a 17-kDa p53 mutant (p53M) in two UPII-p53 mutant mice (lanes 3 and 4; ages 6 and 10 months) and a 53-kDa wild-type p53 (p53W), which is absent in the normal control (lane 2). Asterisk (*) marks a high molecular weight band possibly representing p53 hetero-oligomers. Total urothelial protein extracts from a UPII-SV40T transgenic mouse were used as a positive control for the detection of SV40T-stabilized wild-type p53 (lane 1). The detection of Erk-1 (lower panel) served as a loading control. (b) Immunohistochemical and immunofluorescent staining. Paraffin (a-c) and frozen sections (d-f) of the negative controls (a and d) and transgenic mice (b, c, e and f) were stained with a polyclonal anti-p53 antibody followed by a secondary antibody conjugated with peroxidase (a-c) or fluorescein (d-f). Note that, while no nuclear staining was observed in negative controls (a and d), nuclei of all urothelial layers of the transgenic mice were stained (b, c, e and f), indicating the expression of the mutant p53, and the stabilized wild-type p53 protein (refer to Figure 2a) . Also note the irregularly shaped nuclei at the superficial urothelial layer. All panels are Â 400
Role of p53 deficiency in bladder tumorigenesis J Gao et al that the p53 mutant was expressed in urothelium and that the expressed p53 mutant was capable of interacting with the endogenous p53.
Urothelial nuclear anomaly, hyperplasia and dysplasia in transgenic mice expressing the p53 mutant Urothelia of both transgenic lines exhibited nuclear abnormalities, particularly at the superficial umbrella cell layer. When compared with normal urothelium (panels a and d of Figure 2b ), the nuclei of transgenic urothelium were significantly enlarged, irregularly shaped and dense in chromatin (panels b, c, e and f of Figure 2b ; Figure 3b ). While cell nuclei were rarely seen on thin cross-sections of normal mouse umbrella cells due to a large cytoplasmic/nuclear ratio, the umbrella cell nuclei of the transgenic mice were much more frequently seen due to their enlarged sizes (Figure 3c and h). In addition, there was a marked increase in the number of urothelial cell layer, from 2-3 layers in normal mice (Figure 3a ) to 6-10 layers in transgenic mice (Figure 3c -f). Although normal urothelial cells are mostly quiescent and are negative for proliferative nuclear cell antigen (PCNA; Figure 3g ), urothelium of transgenic mice contained a large number of PCNApositive cells (Figure 3h ). Strongly labeled cells were found in the basal and intermediate layers, consistent with the fact that the proliferative compartment of the urothelium lies in the basal layer, and that the umbrella cells, while expressing large amounts of p53 mutant, are unable to undergo cell division. In both transgenic lines (including the homozygous mice of F8 line), urothelial hyperproliferation occurred in increasing frequency in older mice, with approximately half of all mice developing hyperplasia by 20 months of age (Table 1) . Interestingly, two mice also developed localized dysplasia, where a segment of urothelia exhibited nuclear crowding, increased nuclear/cytoplasmic ratio and loss of cell polarity (Figure 4 ). Despite these hyperproliferative and dysplastic changes, none of the mice observed thus far developed frank bladder carcinomas. These results indicate that, while p53 deficiency predisposes the urothelium to hyperproliferation, it alone is insufficient to induce urothelial tumorigenesis.
Lack of cooperativity between p53 mutant and activated Ha-ras
It has been shown previously that, while the p53 mutant could immortalize primary-cultured fibroblasts, it could not transform them. However, the combination of p53 mutant and activated Ha-ras could efficiently transform fibroblasts (Zambetti et al., 1992; Kikuchi-Yanoshita et al., 1995) . Our recent development of transgenic mice expressing an activated Ha-ras in urothelium (Zhang et al., 2001 ) provided a unique opportunity for us to examine the potential interactions between these two genetic events in vivo. To do this, we crossed the p53 mutant mice with low-copied activated Ha-ras mice (Figure 5a) , the latter of which consistently developed urothelial hyperplasia before 10 months of age. The offspring of such crossbreeding included single transgenic mice that exhibited their parental phenotypes, that is, nuclear abnormalities and moderate hyperplasia in p53 mutant mice (panel b of Figure 5b ) and severe Figure 5b ). Some offspring, that is, the double transgenic mice harbored both genetic alterations ( Figure 5a ) and exhibited both hyperplasia and nuclear abnormalities (panel d of Figure 5b ), but they did not develop any urothelial tumors. These data indicate that p53 deficiency caused by the expression of a dominantnegative mutant of p53 gene does not synergize with Haras activation to enhance bladder tumor formation.
Complete absence of p53 accelerates bladder tumorigenesis in transgenic mice expressing an activated Ha-ras
The fact that the expression of a dominant-negative p53 mutant alone or in conjunction with activated Ha-ras failed to elicit frank urothelial carcinomas raised the possibility that the p53 mutant is insufficient to disable the endogenous wild-type p53 completely. To further examine the role of p53 deficiency in urothelial tumorigenesis, we crossed transgenic mice expressing an activated Ha-ras with p53 knockout mice that lacked p53 expression ( Figure 6) . Consistent with what has been reported, homozygous p53 knockouts could only survive up to 7 months of age because they succumbed to thymic lymphomas and soft-tissue sarcomas (data not shown; Donehower et al., 1992) . The bladders of these p53 knockout-only mice exhibited completely normal urothelial morphology (Figure 7b) . However, the bladders of double transgenic mice nullizygous for p53 gene and transgenic for activated Ha-ras (Figure 7d ) exhibited significantly higher degree of urothelial proliferation than activated Ha-ras-only mice (Figure 7c ). Role of p53 deficiency in bladder tumorigenesis J Gao et al
While activated Ha-ras-only mice never developed bladder tumors before 7 months of age, four out of 13 double transgenic mice (lacking p53 and expressing activated Ha-ras) developed low-grade, superficial papillary tumors between 3-6 months of age (Po0.05;
Figure 7e-i; Table 2 ). In addition, several other double transgenic mice developed high-grade urothelial lesions with profound nuclear abnormalities (Figure 8 ). In comparison with p53 nullizygotes, double transgenic mice heterozygous for p53 and transgenic for activated Ha-ras did not have an increased tumor rate or a higher pathological grade than the activated Ha-ras-only mice ( Table 2 ), suggesting that the mere reduction of p53 gene dosage is insufficient to cooperate with Ha-ras activation to promote urothelial tumorigenesis. These results strongly indicate that the complete inactivation of p53 function is required for its cooperation with oncogenes to induce bladder tumor formation.
Discussion
Role of p53 deficiency in urothelial tumorigenesis
Although a voluminous literature is available on detecting p53 abnormalities in human bladder cancer Figure 6 Generation of double transgenic mice expressing activated Ha-ras and lacking p53. UPII-Ha-ras mutant mice were crossed to p53 knockout mice. Offspring heterozygous for both p53 and Ha-ras mutant were backcrossed to p53 knockout mice, and their offspring were genotyped by Southern blotting using a p53 probe and a UPII probe. (Upper panel) The p53 probe detected a pseudogene fragment (pseudo) in all mice, a knockout allele (KO) in hetero-and homozygous mice and a wild-type (WT) allele in wild type and heterozygous mice (Donehower et al., 1992) . Note the generation of activated H-ras-only mouse (lane 2), the p53 nullizygous mouse (lane 1), p53 heterozygous mouse (lane 3), p53 heterozygous and activated Ha-ras mice (lanes 4 and 5), p53 nullizygous and activated Ha-ras mice (lanes 6-8) Figure 7 Loss of p53 accelerates urothelial proliferation and tumorigenesis in transgenic mice expressing the activated Ha-ras. Offspring (3-7 months old) derived from intercrosses between p53 knockout mice and UPII-Ha-ras mutant mice exhibited different degrees of urothelial proliferation depending on their specific genotypes, including normal morphology in nontransgenic control (a) and p53 nullizygous mouse (b), urothelial hyperplasia in activated Ha-ras-only mouse (c), severe urothelial hyperplasia (d) and lowgrade, superficial papillary tumors in double transgenic mice lacking p53 and expressing activated Ha-ras (lower magnification, e and g; higher magnification, f, h and i). Magnifications: a-d, h, i, Â 200; e, g, Â 50; f, Â 400 Figures 2 and 3 ). This result supports the notion that p53 is a potent inhibitor of cell cycle progression in normal urothelial cells and that p53 dysfunction can release cell cycle restraints and predispose cells to proliferation (Levine, 1997) . However, this proproliferative effect of p53 deficiency on urothelium is only marginal, as the great majority of transgenic mice do not develop urothelial hyperplasia until after a long (10-month) latency (Table 1) . Moreover, with the exception of two cases of dysplasia (Figure 4) , no high-grade bladder lesions were encountered in over 100 transgenic mice analysed, let alone frank urothelial carcinomas. This contrasts with the popular view derived from human correlative studies that p53 deficiency may be responsible for the genesis of highgrade CIS and invasive bladder cancer (Reznikoff et al., 1996; Raghavan, 2003) . Our data, combined with the fact that p53 knockout mice lack any urothelial lesions up to 7 months at which point they succumb to thymic lymphomas and soft-tissue sarcomas (Figure 7b ; Donehower et al., 1992) , strongly suggest that p53 deficiency alone plays an insignificant role in urothelial tumor initiation. Our study provides another example that different tissues have drastically different susceptibility to p53 deficiency (Levine, 1997) . Urothelium, a mostly quiescent epithelium, is much less susceptible to tumorigenesis during p53 deficiency than fast-renewing cells, such as lymphocytes and fibroblasts.
Potential 'gain-of-function' effect of the dominantnegative p53 mutant A somewhat paradoxical observation is that, while p53 mutant mice readily develop urothelial nuclear abnormalities at young ages (Figures 2 and 3 ), p53 knockout mice are devoid of any such changes up to 7 months of age ( Figure 7 ) when further observation is no longer feasible due to animal death. A possible explanation is that the p53 mutant, composed primarily of the tetramerization domain, acts more than just a dominant-negative inhibitor of the wild-type p53. Initially thought to be unable to bind DNA, the C-terminal tetramerizaiton domain has been shown to recognize DNA and catalyse renaturation of complementary oligonucleotides, and to be involved in protein-protein interaction and p53 degradation (Reed et al., 1995; Chene, 2001 ). This may explain why various p53 mutants, both naturally occurring and experimentally created, could augment the tumor-forming abilities of cells lacking endogenous p53 (Chen et al., 1990; Shaulsky et al., 1991) . Our results, combined with those from other investigators, support the concept that p53 mutants can exhibit a 'gain-of-function' effect enhancing cellular growth (Frazier et al., 1998; Lanyi et al., 1998) . Role of p53 deficiency in bladder tumorigenesis J Gao et al
Differential susceptibility of different urothelial layers to p53 deficiency
Virtually all the transgenic lines we have developed thus far show transgene expression in all urothelial layers (Zhang et al., 2001 (Zhang et al., , 1999 Cheng et al., 2002) , but the cellular effects of the transgene expression in different layers appears to be somewhat different. In general, cells in the basal compartment of various transgenic lines express more cell proliferative markers such as PCNA than cells in the superficial layer (Figure 3h ; Cheng et al., 2002) . The fact that the superficial umbrella cells of the p53 mutant mice exhibited large and abnormal nuclei but remain PCNA negative (Figures 2 and 3) suggests that while these terminally differentiated cells can undergo some form of DNA amplification, they no longer possess the proper machinery to allow for cell division. Our results strongly suggest that urothelial tumors are derived from the basal cells, which presumably include the stem cells. That the nuclear abnormalities in p53 mutant mice are confined to the superficial umbrella cells may be due to the fact that the uroplakin II promoter is more active in these cells, leading to higher transgene expression. The abundant expression of the p53 mutant protein, combined with the inability of these terminally differentiated cells to undergo cell division may, therefore, be the underlying cause of the nuclear abnormalities.
Synergism between p53 deficiency and Ha-ras activation
The lack of frank urothelial carcinoma in both p53 mutant and p53 knockout mice raises the possibility that a collaborating genetic defect is needed for urothelial tumorigenesis. The fact that both Ha-ras activation and p53 deficiency occur in human bladder cancer and that they can collaborate in cellular transformation in vitro prompted us to examine their potential synergistic role in vivo. We were surprised to find that the double transgenic mice expressing both the activated Ha-ras and the p53 mutant did not show any enhancement of tumorigenesis ( Figure 5 ), and that, in striking contrast, the double transgenic mice expressing the activated Haras and nullizygous for the p53 gene developed earlyonset urothelial tumors that were either low-grade, superficial papillary or high-grade in nature (Figures 6-8 ). By 7 months of age, when all p53 nullizygotes die of lymphomas, four out of 13 double transgenic mice, but none of the 18 Ha-ras-single transgenic mice, developed urothelial tumors (Table 2) . Within the same time frame, however, double transgenic expressing the activated Haras but heterozygous for the p53 gene did not exhibit any bladder tumors. This suggests that p53 made by the remaining allele is sufficient to counter the oncogenic effects of Ha-ras. A similar situation may have occurred in the p53 mutant mice, where the mutant may be insufficient to inactivate completely the endogenous p53, thus explaining why double transgenic mice expressing the p53 mutant and activated Ha-ras, even after longterm follow-up, failed to show any synergy in tumorigenesis. Additional support for the dosage dependence of p53 gene loss comes from transgenic mice expressing low levels of the SV40T antigen. Although SV40T antigen is known to inactivate p53 functionally, 86% of SV40T-induced bladder CIS had an allelic loss of p53 gene, thereby further decreasing the p53 gene dosage (Cheng et al., 2003) . These results strongly suggest that the complete absence of p53 function is a prerequisite for its collaboration with oncogenic events to induce bladder tumor formation.
Owing to the early lethality of the whole-body p53 knockout, it was not possible to study the long-term collaborative effects between Ha-ras activation and p53 absence. Questions remain, therefore, as to whether p53 deficiency can promote at a later stage the transition from bladder superficial papillary tumors to invasive tumors. It also remains to be seen whether additional genetic alterations are required to yield more aggressive bladder cancers Cote et al., 1998; Grossman et al., 1998) . The generation of urothelium-specific knockout of p53 and subsequent crossbreeding with mice harboring various genetic defects should help further define the role of p53 in urothelial tumorigenesis and progression.
Materials and methods
Generation of UPII-p53-M transgenic mice
A 317-bp truncated form of mouse p53 cDNA that encodes the first 14 amino acids and the last 89 amino acids was PCR amplified from pCMVDD plasmid (a kind gift from Dr Moshe Oren of The Weizmann Institute of Science; Shaulian et al., 1992) , using a forward primer (5 0 -ACTGGATGACTGC-CATGGAGG-3 0 ) and reverse primer (5 0 -TCAGTCTGAGT-CAGGCCCCA-3 0 ), both of which were supplemented with a BamHI site to facilitate cloning. The PCR product was subcloned into a TA cloning vector (Invitrogen) and was sequenced for its authenticity. After BamHI digestion, the PCR product was cloned between a 3.6-kb mouse uroplakin II promoter and a 500-bp mouse protamine 1 fragment containing a polyA signal. The orientation of the cloned BamHI fragment in relation to the uroplakin II promoter was verified by restriction digestion and sequencing. The 4.4-kb chimeric gene containing the mouse UPII promoter, the truncated p53 cDNA and the mouse protamine 1 fragment were retrieved en bloc by KpnI/HindIII digestion. After gel and column purifications, the chimeric gene was microinjected into fertilized eggs derived from FVB/N inbred mice according to an established protocol (Brinster et al., 1981) .
Detection of dominant-negative p53 mutant in transgenic mice
Transgenic mice were identified with Southern blot analysis of genomic DNA of tail biopsies (Zhang et al., 1999; Cheng et al., 2002) . DNA of founder animals was digested with BstXI, electrophoresed, transferred onto nylon membrane and probed with a 32 P-labeled UPII probe (P1; see Figure 1 ) or a mouse protamine 1 probe (P2). DNA of F1 and F2 animals was digested with NcoI for better resolution of the transgene and the endogenous uroplakin II fragments.
The expression of the p53 mutant in urothelia of transgenic mice at RNA level was assessed using RT-PCR. Briefly, mouse urothelial cells were scraped off from bladder mucosa and total RNA was extracted using an RNA extraction kit (Promega).
Total RNA (2 mg) was reverse transcribed and the second strand of cDNA was synthesized. One-fifth of the doublestranded cDNA was subjected to PCR amplification using p53 primers described above under the following conditions: 941C for 5 min, 581C for 30 min, 721C for 1 min for 35 cycles and 941C for 5 min, 581C for 30 min, 721C for 8 min for the last cycle. Parallel amplification of GAPDH was used as an internal control.
The expression of the p53 mutant at the protein level was determined using Western blot analysis. Total urothelial proteins were dissolved in 5% SDS, resolved on a 10% SDS-PAGE and transferred onto an Immobilon PVDF membrane. The membrane was then incubated with a polyclonal antibody against mouse p53 (Ab-7; Oncogene Science) followed by a secondary antibody conjugated with horseradish peroxidase. After washing in phosphate-buffered saline, the membrane was developed with chemiluminescent reagents (Perkin-Elmer Life Sciences, Inc.) and exposed to Xray film for 5 min. Antibody against Erk-1 was used as a loading control.
Histopathology, immunohistochemistry and immunofluorescence
Freshly dissected mouse bladders were bisected, fixed in 10% buffered formalin and embedded in paraffin. Sections (5 mm) were routinely stained with hemotoxylin and eosin for histological examination. Alternatively, deparaffinized sections were microwaved in citric acid (pH 6.0) for 20 min for antigen retrieval and stained with a polyclonal antibody against p53 (see above), followed by a secondary antibody conjugated with horseradish peroxidase. Selected sections were also stained with an antibody against proliferative nuclear antigen (PCNA; Dako). In addition, anti-p53 antibody was employed on frozen bladder sections, followed by a secondary antibody conjugated with fluorescein.
Generation of double transgenic mice-expressing p53 mutant and Ha-ras mutant Transgenic mice harboring the p53 mutant (line F8) were crossed to transgenic mice harboring low-copy numbers of the Ha-ras mutant (line F5) and developing urothelial hyperplasia before 10 months of age (Zhang et al., 2001) . Genotypes of the offspring from the crossbreeding were determined by Southern blot analysis. A uroplakin II probe permitted the detection of the endogenous uroplakin II gene fragment (1.4 kb), the uroplakin II-p53 mutant transgene fragment (1.1 kb) and the uroplakin II-Ha-ras mutant transgene fragment (1.7 kb).
Generation of double transgenic mice lacking p53 and expressing Ha-ras mutant Uroplakin II-Ha-ras mutant mice were crossed to p53 knockout mice (Jackson Laboratories; Donehower et al., 1992) . Mice heterozygous for the p53 gene and transgenic for uroplakin IIHa-ras mutant transgene were backcrossed to p53 knockouts to obtain double transgenic mice lacking the p53 gene and transgenic for uroplakin II-Ha-ras mutant. Genotyping was performed using Southern blot analysis first with a p53 cDNA probe (kindly provided by Dr Lawrence Donehower of Baylor College of Medicine) for p53 gene status, and later after heat stripping, with a uroplakin II probe for uroplakin II-Ha-ras mutant status.
